ResearcherMayo ClinicActive in the last 2 years
Hari Krishnareddy Rachamala
Matched on OpenAlex author ID A5111172992, A5111327445. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 4, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2024: 1 paper · 2025: 2 papers · 2026: 3 papers
Papers 6
- AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117777↗
- Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal Adenocarcinoma Therapy. First author DOI 10.1021/acsabm.5c02077↗
- Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Therapeutic Synergy. First author DOI 10.3390/cells15090845↗
- Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in … Co-author DOI 10.1053/j.gastro.2024.09.009↗
- Lipid Nanoparticle-Mediated RNAi Against GIPC1 Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/pharmaceutics17101334↗
- Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.mtbio.2024.101199↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Debabrata Mukhopadhyay · 5 shared papers, 2024–2026 · strength 1.37
- Paper Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidenc… DOI 10.3390/cells15090845↗
- Paper Lipid Nanoparticle-Mediated RNAi Against GIPC1 Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/pharmaceutics17101334↗
- Paper Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal… DOI 10.1021/acsabm.5c02077↗
- Krishnendu Pal · 5 shared papers, 2024–2026 · strength 1.32
- Paper Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Ef… DOI 10.1053/j.gastro.2024.09.009↗
- Paper Lipid Nanoparticle-Mediated RNAi Against GIPC1 Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/pharmaceutics17101334↗
- Paper Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal… DOI 10.1021/acsabm.5c02077↗
- Santanu Bhattacharya · 4 shared papers, 2024–2026 · strength 1.14
- Paper Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidenc… DOI 10.3390/cells15090845↗
- Paper Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Ef… DOI 10.1053/j.gastro.2024.09.009↗
- Paper Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal… DOI 10.1021/acsabm.5c02077↗
- Naga Malleswara Rao Nakka · 4 shared papers, 2024–2026 · strength 1.01
- Paper Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Ef… DOI 10.1053/j.gastro.2024.09.009↗
- Paper Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal… DOI 10.1021/acsabm.5c02077↗
- Paper AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117777↗
- Hani M. Babiker · 3 shared papers, 2024–2026 · strength 0.79
- Paper Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidenc… DOI 10.3390/cells15090845↗
- Paper AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117777↗
- Paper Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenoca… DOI 10.1016/j.mtbio.2024.101199↗
- Douaa Albelal · 1 shared paper, 2026 · strength 0.36
- Vijay Sagar Madamsetty · 1 shared paper, 2025 · strength 0.30
- Debabrata Mukhopadhyay · 1 shared paper, 2025 · strength 0.30
- Tanmay Kulkarni · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.